Stressed hearts inflame the body (in a good way)

Heart failure is a global health problem, with an estimated 30–50 million patients diagnosed worldwide (1, 2). Therapeutic advances have reduced early mortality; however, morbidity caused by damaged or failing ventricles remains high. Indeed, heart failure is the most common cause for hospitalization in elderly individuals, with recalcitrant 5-y survival rates remaining worse than most cancers (2). Sustained stress from abnormal mechanical load, neurohormone stimulation, and genetic defects are all potent inducers of heart failure (3, 4). These trigger conversations among vascular, muscle, and inflammatory cells, as well as fibroblasts using a myokine/cytokine vocabulary that can be shared by the multiple cell types or be more specific. As recently reviewed by Ghigo et al. (5), growing evidence has positioned the myocyte as a “Master and Commander” for coordinating interstitial responses to myocardial stress, including fibrosis, vascular remodeling, and inflammation. In hearts subjected to pressure overload, myocyte secretion of interleukins (IL-1β, -6, -18), TNF-α, receptor activator of NF-κB ligand, and macrophage chemoattractant protein-1 all signal to inflammatory responses, whereas ischemic disease engages additional factors, such as the adhesion molecules ICAM-1 and VCAM-1, and anti-inflammatory growth differentiation factor 15 (5). Depending on the stress, this coordinated inflammatory conversation can impact myocyte growth and survival, as well as remove damaged or dead cells.

[1]  Richard T. Lee,et al.  Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33 , 2015, Proceedings of the National Academy of Sciences.

[2]  E. Braunwald The war against heart failure: the Lancet lecture , 2015, The Lancet.

[3]  J. Girard,et al.  IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy. , 2014, Current opinion in immunology.

[4]  G. Ertl,et al.  Interleukin-13 Deficiency Aggravates Healing and Remodeling in Male Mice After Experimental Myocardial Infarction , 2014, Circulation. Heart failure.

[5]  E. Schiffrin,et al.  Dual opposing roles of adaptive immunity in hypertension. , 2014, European heart journal.

[6]  E. Hirsch,et al.  Myocyte signalling in leucocyte recruitment to the heart. , 2014, Cardiovascular research.

[7]  Naoki Sato,et al.  The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. , 2014, Journal of the American College of Cardiology.

[8]  Dong I. Lee,et al.  Cardiomyocyte-Specific Transforming Growth Factor &bgr; Suppression Blocks Neutrophil Infiltration, Augments Multiple Cytoprotective Cascades, and Reduces Early Mortality After Myocardial Infarction , 2014, Circulation research.

[9]  E. Schiffrin Immune mechanisms in hypertension and vascular injury. , 2014, Clinical science.

[10]  D. Kass,et al.  Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. , 2011, The Journal of clinical investigation.

[11]  GiuseppeLembo,et al.  Distinct Effects of Leukocyte and Cardiac Phosphoinositide 3-Kinase γ Activity in Pressure Overload–Induced Cardiac Failure , 2011 .

[12]  E. Hirsch,et al.  Distinct Effects of Leukocyte and Cardiac Phosphoinositide 3-Kinase &ggr; Activity in Pressure Overload–Induced Cardiac Failure , 2011, Circulation.

[13]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[14]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[15]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[16]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[17]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[18]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[19]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[20]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.

[21]  T. Doetschman,et al.  TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II , 2002 .